CN118436778A - Multi-effect plant antibacterial and antiviral preparation - Google Patents
Multi-effect plant antibacterial and antiviral preparation Download PDFInfo
- Publication number
- CN118436778A CN118436778A CN202410867601.6A CN202410867601A CN118436778A CN 118436778 A CN118436778 A CN 118436778A CN 202410867601 A CN202410867601 A CN 202410867601A CN 118436778 A CN118436778 A CN 118436778A
- Authority
- CN
- China
- Prior art keywords
- extract
- preparation
- antiviral
- effect plant
- antibacterial
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 64
- 230000000840 anti-viral effect Effects 0.000 title claims abstract description 52
- 230000000844 anti-bacterial effect Effects 0.000 title claims description 46
- 239000000284 extract Substances 0.000 claims abstract description 46
- 241000196324 Embryophyta Species 0.000 claims abstract description 45
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims abstract description 37
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims abstract description 24
- 235000015489 Emblica officinalis Nutrition 0.000 claims abstract description 21
- 108060003951 Immunoglobulin Proteins 0.000 claims abstract description 16
- 102000016943 Muramidase Human genes 0.000 claims abstract description 16
- 108010014251 Muramidase Proteins 0.000 claims abstract description 16
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 claims abstract description 16
- 210000002969 egg yolk Anatomy 0.000 claims abstract description 16
- 102000018358 immunoglobulin Human genes 0.000 claims abstract description 16
- 235000010335 lysozyme Nutrition 0.000 claims abstract description 16
- 239000004325 lysozyme Substances 0.000 claims abstract description 16
- 229960000274 lysozyme Drugs 0.000 claims abstract description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 16
- 239000008367 deionised water Substances 0.000 claims abstract description 15
- 229910021641 deionized water Inorganic materials 0.000 claims abstract description 15
- 241000205585 Aquilegia canadensis Species 0.000 claims abstract description 14
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims abstract description 13
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims abstract description 13
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims abstract description 13
- 229960000502 poloxamer Drugs 0.000 claims abstract description 13
- 229920001983 poloxamer Polymers 0.000 claims abstract description 13
- 239000000811 xylitol Substances 0.000 claims abstract description 13
- 235000010447 xylitol Nutrition 0.000 claims abstract description 13
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims abstract description 13
- 229960002675 xylitol Drugs 0.000 claims abstract description 13
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims abstract description 12
- 229930003268 Vitamin C Natural products 0.000 claims abstract description 12
- 235000019154 vitamin C Nutrition 0.000 claims abstract description 12
- 239000011718 vitamin C Substances 0.000 claims abstract description 12
- 244000119298 Emblica officinalis Species 0.000 claims abstract description 5
- 230000003385 bacteriostatic effect Effects 0.000 claims abstract description 3
- 241000207929 Scutellaria Species 0.000 claims abstract 2
- 238000001914 filtration Methods 0.000 claims description 20
- 239000000463 material Substances 0.000 claims description 19
- 102000002322 Egg Proteins Human genes 0.000 claims description 15
- 108010000912 Egg Proteins Proteins 0.000 claims description 15
- 235000013345 egg yolk Nutrition 0.000 claims description 15
- 239000007788 liquid Substances 0.000 claims description 15
- 238000005303 weighing Methods 0.000 claims description 11
- 235000011187 glycerol Nutrition 0.000 claims description 10
- 238000003756 stirring Methods 0.000 claims description 9
- 238000007689 inspection Methods 0.000 claims description 8
- 239000000706 filtrate Substances 0.000 claims description 5
- 238000010438 heat treatment Methods 0.000 claims description 5
- 229960005150 glycerol Drugs 0.000 claims description 4
- 238000001816 cooling Methods 0.000 claims description 3
- 239000010404 Scutellaria baicalensis extract Substances 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 229930003231 vitamin Natural products 0.000 claims 1
- 235000013343 vitamin Nutrition 0.000 claims 1
- 239000011782 vitamin Substances 0.000 claims 1
- 229940088594 vitamin Drugs 0.000 claims 1
- 150000003722 vitamin derivatives Chemical class 0.000 claims 1
- 239000003443 antiviral agent Substances 0.000 abstract description 2
- 235000013399 edible fruits Nutrition 0.000 abstract description 2
- 238000012360 testing method Methods 0.000 description 28
- 239000011550 stock solution Substances 0.000 description 21
- 230000000052 comparative effect Effects 0.000 description 19
- 240000009120 Phyllanthus emblica Species 0.000 description 16
- 230000005764 inhibitory process Effects 0.000 description 12
- 241000191967 Staphylococcus aureus Species 0.000 description 11
- 241000222122 Candida albicans Species 0.000 description 10
- 241000050051 Chelone glabra Species 0.000 description 10
- 229940095731 candida albicans Drugs 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 241000588724 Escherichia coli Species 0.000 description 9
- 241000700605 Viruses Species 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 210000000214 mouth Anatomy 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 7
- 241000283977 Oryctolagus Species 0.000 description 7
- 238000001514 detection method Methods 0.000 description 7
- 210000001508 eye Anatomy 0.000 description 7
- 206010015946 Eye irritation Diseases 0.000 description 6
- 208000000474 Poliomyelitis Diseases 0.000 description 6
- 231100000013 eye irritation Toxicity 0.000 description 6
- 238000004659 sterilization and disinfection Methods 0.000 description 6
- 230000006378 damage Effects 0.000 description 5
- 210000000554 iris Anatomy 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 230000001154 acute effect Effects 0.000 description 4
- 229910052785 arsenic Inorganic materials 0.000 description 4
- RQNWIZPPADIBDY-UHFFFAOYSA-N arsenic atom Chemical compound [As] RQNWIZPPADIBDY-UHFFFAOYSA-N 0.000 description 4
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 4
- 229910052753 mercury Inorganic materials 0.000 description 4
- 238000011056 performance test Methods 0.000 description 4
- 230000001954 sterilising effect Effects 0.000 description 4
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 3
- 206010010726 Conjunctival oedema Diseases 0.000 description 3
- 230000001488 breeding effect Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 210000004087 cornea Anatomy 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000002779 inactivation Effects 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 230000002147 killing effect Effects 0.000 description 3
- 239000005995 Aluminium silicate Substances 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 235000012211 aluminium silicate Nutrition 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000002155 anti-virotic effect Effects 0.000 description 2
- 210000000795 conjunctiva Anatomy 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 229910001385 heavy metal Inorganic materials 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 2
- 244000000010 microbial pathogen Species 0.000 description 2
- 230000002906 microbiologic effect Effects 0.000 description 2
- 231100000286 mucous membrane, eye irritation or corrosion testing Toxicity 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 239000008354 sodium chloride injection Substances 0.000 description 2
- 239000012086 standard solution Substances 0.000 description 2
- 208000028006 Corneal injury Diseases 0.000 description 1
- 241000709701 Human poliovirus 1 Species 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 208000025157 Oral disease Diseases 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 241000193996 Streptococcus pyogenes Species 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 206010046306 Upper respiratory tract infection Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 208000007565 gingivitis Diseases 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 238000001095 inductively coupled plasma mass spectrometry Methods 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 208000030194 mouth disease Diseases 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 235000019633 pungent taste Nutrition 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/47—Euphorbiaceae (Spurge family), e.g. Ricinus (castorbean)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/35—Caprifoliaceae (Honeysuckle family)
- A61K36/355—Lonicera (honeysuckle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/539—Scutellaria (skullcap)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/02—Local antiseptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01017—Lysozyme (3.2.1.17)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nutrition Science (AREA)
- Molecular Biology (AREA)
- Neurosurgery (AREA)
- Virology (AREA)
- Physiology (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Abstract
The invention provides a multi-effect plant bacteriostatic and antiviral preparation, which belongs to the technical field of antiviral drug preparations, and comprises the components of 0.5-1.8% of emblic leafflower fruit extract, 0.5-1.2% of lysozyme, 0.2-0.8% of honeysuckle extract, 0.3-0.8% of scutellaria extract, 0.2-1.2% of yolk immunoglobulin, 0.2-0.8% of vitamin C, 3.0-6.0% of xylitol, 1.0-5.0% of glycerol, 0.3-1.0% of poloxamer and the balance deionized water.
Description
Technical Field
The invention relates to the technical field of oral antibacterial and antiviral pharmaceutical preparations, in particular to a multi-effect plant antibacterial and antiviral preparation.
Background
The oral cavity is one of the main ways for bacteria, viruses and other pathogenic microorganisms to enter the human body, and after the bacteria, viruses and other pathogenic microorganisms enter the oral cavity, oral diseases such as decayed teeth, gingivitis, dental ulcer and the like can be caused; it is also possible to induce upper respiratory tract infection such as pharyngitis and digestive tract infection in the descending direction, and also possible to induce systemic diseases; therefore, the antibacterial and antiviral protection of the oral cavity is particularly important.
At present, the oral care products or medicines on the market mainly have the effects of sterilization and anti-inflammation, have single effect, and basically have no antibacterial and antiviral effects or have weaker antibacterial and antiviral effects.
Therefore, the application provides a multi-effect plant antibacterial and antiviral preparation.
Disclosure of Invention
In order to overcome the problems in the background technology, the invention aims to provide a multi-effect plant antibacterial and antiviral preparation, and solves the problems that the oral care products or medicines in the current market mainly take sterilization and anti-inflammation as main effects and have single effect.
In order to achieve the above purpose, the invention is realized by the following technical scheme:
A multi-effect plant antibacterial and antiviral preparation comprises the following components in percentage by weight: 0.5 to 1.8 percent of phyllanthus emblica extract, 0.5 to 1.2 percent of lysozyme, 0.2 to 0.8 percent of honeysuckle extract, 0.3 to 0.8 percent of baical skullcap root extract, 0.2 to 1.2 percent of egg yolk immunoglobulin, 0.2 to 0.8 percent of vitamin C, 3.0 to 6.0 percent of xylitol, 1.0 to 5.0 percent of glycerol, 0.3 to 1.0 percent of poloxamer and the balance of deionized water.
Further, the multi-effect plant antibacterial and antiviral preparation comprises the following components in percentage by weight: 1.0% of phyllanthus emblica extract, 1.0% of lysozyme, 0.5% of honeysuckle extract, 0.5% of baical skullcap root extract, 0.5% of egg yolk immunoglobulin, 0.5% of vitamin C, 5.0% of xylitol, 3.0% of glycerol, 0.5% of poloxamer and 87.5% of deionized water.
The application also provides a preparation method of the multi-effect plant antibacterial and antiviral preparation, which comprises the following steps:
S1: weighing the phyllanthus emblica extract, the honeysuckle extract, the baical skullcap root extract and deionized water according to the weight percentage, and adding the materials into a liquid preparation tank;
S2: heating the liquid preparation tank and stirring to 80 ℃ to dissolve the materials;
S3: filtering the fully dissolved material for the first time, wherein the filtering precision is less than or equal to 5um;
S4: cooling the filtrate to 50deg.C, adding lysozyme, egg yolk immunoglobulin, vitamin C, xylitol, glycerol, poloxamer, stirring for dissolving;
s5: and (3) carrying out secondary filtration on the dissolved material, wherein the filtration precision is less than or equal to 1.5um, and filling the material after inspection.
The invention has the beneficial effects that:
(1) The traditional Chinese medicine extracts such as the phyllanthus emblica and the lysozyme and the egg yolk immunoglobulin have synergistic effect on bacteriostasis and antivirus, the components of the phyllanthus emblica extract are slightly acidic, the preparation can adjust the pH of the oral cavity in the oral cavity to form a proper acidic environment, the stable activity of the components is maintained, and the dual effects of bacteriostasis and antivirus are good;
(2) The multi-effect plant antibacterial and antiviral preparation provided by the application can be adhered to the oral cavity after contacting with the mucous membrane of a human body, has long-lasting effect, and can keep the oral cavity healthy for a long time;
(3) The multi-effect plant antibacterial and antiviral preparation provided by the application is prepared from honeysuckle, baical skullcap root and emblic leafflower fruit extract plant components, has mild effect of no pungent taste, and can improve the use experience of long-term use.
Detailed Description
In order to make the objects, technical solutions and advantageous effects of the present invention more apparent, preferred embodiments of the present invention will be described in detail below to facilitate understanding by a skilled person.
Example 1
A multi-effect plant antibacterial and antiviral preparation comprises the following components in percentage by weight:
1.0% of phyllanthus emblica extract, 1.0% of lysozyme, 0.5% of honeysuckle extract, 0.5% of baical skullcap root extract, 0.5% of egg yolk immunoglobulin, 0.5% of vitamin C, 5.0% of xylitol, 3.0% of glycerol, 0.5% of poloxamer and 87.5% of deionized water.
A multi-effect plant antibacterial and antiviral preparation comprises the following preparation method:
S1: weighing 1.0% of phyllanthus emblica extract, 0.5% of honeysuckle extract, 0.5% of baical skullcap root extract and deionized water according to weight percentage, and adding into a liquid preparation tank;
S2: heating the liquid preparation tank and stirring to 80 ℃ to dissolve the materials;
S3: filtering the fully dissolved material for one time with the filtering precision of 5um;
s4: cooling the filtrate to 50deg.C, weighing and adding 1.0% lysozyme, 0.5% egg yolk immunoglobulin, 0.5% vitamin C, 5.0% xylitol, 3.0% glycerol, and 0.5% poloxamer by weight percentage, stirring for dissolving;
s5: and (5) carrying out secondary filtration on the dissolved material, wherein the filtration precision is 1.5um, and filling and producing after inspection.
Example 2
A multi-effect plant antibacterial and antiviral preparation comprises the following components in percentage by weight:
0.5% of phyllanthus emblica extract, 0.5% of lysozyme, 0.2% of honeysuckle extract, 0.3% of baical skullcap root extract, 0.2% of egg yolk immunoglobulin, 0.2% of vitamin C, 3.0% of xylitol, 1.0% of glycerin, 0.3% of poloxamer and the balance of deionized water.
A multi-effect plant antibacterial and antiviral preparation comprises the following preparation method:
S1: weighing 0.5% of phyllanthus emblica extract, 0.2% of honeysuckle extract, 0.3% of baical skullcap root extract and deionized water according to weight percentage, and adding into a liquid preparation tank;
S2: heating the liquid preparation tank and stirring to 80 ℃ to dissolve the materials;
S3: filtering the fully dissolved material for one time with the filtering precision of 5um;
s4: when the temperature of the filtrate is reduced to 50 ℃, weighing and adding 0.5 percent of lysozyme, 0.2 percent of egg yolk immunoglobulin, 0.2 percent of vitamin C, 3.0 percent of xylitol, 1.0 percent of glycerol and 0.3 percent of poloxamer according to the weight percentage, stirring and dissolving;
s5: and (5) carrying out secondary filtration on the dissolved material, wherein the filtration precision is 1.5um, and filling and producing after inspection.
Example 3
A multi-effect plant antibacterial and antiviral preparation comprises the following components in percentage by weight:
1.8% of phyllanthus emblica extract, 1.2% of lysozyme, 0.8% of honeysuckle extract, 0.8% of baical skullcap root extract, 1.2% of egg yolk immunoglobulin, 0.8% of vitamin C, 6.0% of xylitol, 5.0% of glycerin, 1.0% of poloxamer and the balance of deionized water.
A multi-effect plant antibacterial and antiviral preparation comprises the following preparation method:
s1: weighing 1.8% of phyllanthus emblica extract, 0.8% of honeysuckle extract, 0.8% of baical skullcap root extract and deionized water according to weight percentage, and adding into a liquid preparation tank;
S2: heating the liquid preparation tank and stirring to 80 ℃ to dissolve the materials;
S3: filtering the fully dissolved material for one time with the filtering precision of 5um;
S4: when the temperature of the filtrate is reduced to 50 ℃, 1.2 percent of lysozyme, 1.2 percent of egg yolk immunoglobulin, 0.8 percent of vitamin C, 6.0 percent of xylitol, 5.0 percent of glycerol and 1.0 percent of poloxamer are weighed according to weight percentage and added, stirred and dissolved;
s5: and (5) carrying out secondary filtration on the dissolved material, wherein the filtration precision is 1.5um, and filling and producing after inspection.
Comparative example 1:
Comparative example 1 differs from example 1 in that: the weighing amount of the phyllanthus emblica extract is 0.4%.
Comparative example 2:
Comparative example 2 is different from example 1 in that: the weighing amount of the phyllanthus emblica extract is 3%.
Comparative example 3:
Comparative example 3 is different from example 1 in that: the weighing amount of the phyllanthus emblica extract is 4%.
Experimental example 1:
performing a bacteriostasis ring performance test on the multi-effect plant bacteriostasis and antiviral preparation obtained in the embodiment 1;
1. Equipment and method for manufacturing the same
1. Test sample: a multi-effect plant antibacterial and antiviral preparation;
2. Test strain: coli (8099), staphylococcus aureus (ATCC 6538), candida albicans (ATCC 10231), all were tested on 4 th generation fresh slant cultures. The strains are provided by the research and development center of food microbial safety engineering technology in Guangdong province.
3. Instrument apparatus: KC-SP-YQ-116 vernier caliper, KC-SP-YQ-178 electrothermal constant temperature incubator, KC-SP-YQ-586 biosafety cabinet and KC-SP-YQ-207 pressure steam sterilizing pot.
2. Experimental method
1. The test basis is as follows: disinfection technical Specification 2.1.8.2 (2002 edition).
2. Inspection conditions: the temperature is 21-22 ℃, and the relative humidity is 51-52%.
3. Preparation of the samples: and (5) raw liquid.
4. Concentration of inoculum: 5X 10 5CFU/mL~5×106 CFU/mL.
3. Experimental data
The bacteriostasis ring data of the multi-effect plant bacteriostasis and antiviral preparation on escherichia coli, staphylococcus aureus and candida albicans are shown in table 1, table 2 and table 3 respectively:
TABLE 1 diameter of inhibition ring of stock solution for E.coli
TABLE 2 diameter of inhibition ring of sample stock solution against Staphylococcus aureus
TABLE 3 diameter of the inhibition ring of sample stock solution against Candida albicans
4. Conclusion of experiment:
Under experimental conditions, the multi-effect plant antibacterial and antiviral preparation has antibacterial effect on average antibacterial ring diameter data of escherichia coli, staphylococcus aureus and candida albicans according to the multi-effect plant antibacterial and antiviral preparation.
Experimental example 2:
performing a bacteriostasis ring performance test on the multi-effect plant bacteriostasis and antiviral preparation obtained in the comparative example 1; the test sample is the multi-effect plant antibacterial and antiviral preparation stock solution prepared in comparative example 1, and the experimental equipment and the experimental method are the same as those in experimental example 1.
Experimental data
The bacteriostasis ring data of the multi-effect plant bacteriostasis and antiviral preparation on escherichia coli, staphylococcus aureus and candida albicans are shown in tables 4,5 and 6 respectively:
TABLE 4 diameter of inhibition ring of stock solution for E.coli
TABLE 5 diameter of inhibition ring of sample stock solution against Staphylococcus aureus
TABLE 6 diameter of the inhibition ring of sample stock solution against Candida albicans
Experimental example 3:
Performing a bacteriostasis ring performance test on the multi-effect plant bacteriostasis and antiviral preparation obtained in the comparative example 2; the test sample is the multi-effect plant antibacterial and antiviral preparation stock solution prepared in comparative example 2, and the experimental equipment and the experimental method are the same as those in experimental example 1.
Experimental data
The bacteriostasis ring data of the multi-effect plant bacteriostasis and antiviral preparation on escherichia coli, staphylococcus aureus and candida albicans are shown in table 7, table 8 and table 9 respectively:
TABLE 7 diameter of inhibition ring of stock solution for E.coli
TABLE 8 diameter of inhibition ring of sample stock solution against Staphylococcus aureus
Table 9 diameter of the inhibition Ring of sample stock solution against Candida albicans
Experimental example 4:
Performing a bacteriostasis ring performance test on the multi-effect plant bacteriostasis and antiviral preparation obtained in the comparative example 3; the test sample is the multi-effect plant antibacterial and antiviral preparation stock solution prepared in comparative example 3, and the experimental equipment and the experimental method are the same as those in experimental example 1.
Experimental data
The bacteriostasis ring data of the multi-effect plant bacteriostasis and antiviral preparation on escherichia coli, staphylococcus aureus and candida albicans are shown in table 10, table 11 and table 12 respectively:
table 10 diameter of inhibition Ring of stock solution for E.coli
TABLE 11 diameter of inhibition ring of sample stock solution against Staphylococcus aureus
Table 12 diameter of the inhibition Ring of the sample stock solution against Candida albicans
Conclusion: the samples prepared in the embodiment 1, the comparative example 2 and the comparative example 3 have antibacterial effect, and the experimental example 1 has the best antibacterial and antiviral effects;
comparative example 1 has a low content of phyllanthus emblica extract, has less influence on the pH of the oral environment, and lysozyme and egg yolk immunoglobulin do not reach the optimal stable activity in the pH of the oral environment, and the retention and antibacterial and antiviral effects in the oral cavity are inferior to those of example 1.
Comparative examples 2 and 3 are superior to example 1 in that the content of the phyllanthus emblica extract is high, the influence on the pH of the oral environment is great, the pH of the oral environment is higher, the lysozyme and the egg yolk immunoglobulin cannot reach the optimal stable activity, and the antibacterial and antiviral effects are inferior to those of example 1.
Experimental example 5
Virus killing effect test for multi-effect plant antibacterial and antiviral preparation
1. Test equipment
1. Test virus strain: poliovirus-1 vaccine strains;
2. Host name: ve58 cells;
3. And (3) equipment: cell culture bottle 96-well culture plate, constant temperature water bath box, carbon dioxide incubator, laminar flow super clean bench, low temperature refrigerator (-20 ℃, -80 ℃), liquid nitrogen tank, inverted microscope, centrifuge, adjustable pipettor and matched disposable plastic suction head.
2. The detection method comprises the following steps: sterilizing technical Specification 2002 edition-2.1.1.10.7 poliomyelitis Virus inactivation experiment
3. Detecting a sample: example 1 sample, comparative example 2 sample, comparative example 3 sample correspond to test group 1, test group 2, test group 3, test group 4, respectively; deionized water was used as control 1, control 2, control 3, control 4.
4. Principle of experiment
1. Measuring the amount of poliomyelitis in samples before and after the action of the sample (or an experimental group and a control group) by using a cell infection method, determining the infection titer of each group of viruses by taking cytopathy as a judgment index, and calculating the inactivation rate of the disinfectant on the poliomyelitis;
2. the test group sets a proper concentration and action time group according to the estimated killing or inactivating dose of the tested sample to other microorganisms;
3. The control group uses deionized water to replace a sample, poliomyelitis suspension is added according to the specified steps of the test group for test and culture, whether the poliomyelitis grows well or not is observed, meanwhile, a complete culture medium without poliomyelitis is used as a negative control, whether pollution exists in the culture medium is observed, and whether cells grow well or not is observed.
5. Detection data: as in Table 13
Table 13 sample stock virus inactivation test
Conclusion: the samples of the invention in the embodiment 1 and the comparative examples 1,2 and 3 have good antibacterial and antiviral effects, the four groups of samples have no obvious difference in the effect of killing viruses, and the sample of the embodiment 1 has the best antibacterial effect.
Animal experiment:
The multi-effect plant antibacterial and antiviral preparation prepared in the example 1 is subjected to an acute eye irritation test;
1. experimental materials and animals
1. Sample to be tested
Name: multi-effect plant antibacterial and antiviral preparation, the character: liquid
2. Animals
Name: new Zealand rabbit
Grade: common grade
Number and sex: 3, male
Weight of: 2.0 kg-2.5 kg
Breeding unit: breeding center for cultivating Jinan Kaolin horn
Production license number: SCXK (robust) 2020 0004
Quality certification number: no.370822211100008622
3. Raising environment
Temperature: 16-26 DEG C
Relative humidity: 40 to 70 percent
4. Feed stuff
Name: rabbit feed
The manufacturing factory: breeding center for cultivating Jinan Kaolin horn
Production license number: SCXK (robust) 2018 0010
Quality certification number: no.3708242100002451
2. Method of
1. The test basis is as follows: acute eye irritation test in disinfection Specification (2002 edition) 2.3.4.
2. Sample preparation: a multi-effect plant antibacterial and antiviral preparation stock solution.
3. The test method comprises the following steps:
3.1 preparation of experimental animals: new Zealand rabbits were pre-raised in the laboratory animal house environment for 3 days to suit the environment. Each New Zealand rabbit was examined 24 hours before the test and no abnormalities were found in both eyes, and could be used for the test.
3.2 Method of contamination: by adopting a self-contrast method on the left side and the right side of the homobody, 0.1mL of a test object stock solution is dripped into a conjunctival sac of the left eye, the eye is passively closed for 4s, and the eye is rinsed by sodium chloride injection after about 30 s. Sodium chloride injection was administered as a negative control by the right eye in an amount of 0.1 mL.
3.3 Injury and recovery of conjunctiva, iris and cornea of New Zealand rabbit eyes after eye drop for 1h, 24h, 48h, 72h were visually observed and recorded. No stimulus response occurred within 72h and the test ended. The acute eye irritation response of New Zealand rabbit eyes, cornea, iris and conjunctiva was scored according to the scoring criteria of Table 2-13 rabbit acute eye irritation response in technical Specification for disinfection (2002 edition) 2.3.4, and the "average score" for each animal in four different observation times (24 h, 48h and 72 h) for cornea damage, iris damage, conjunctival congestion and conjunctival edema was calculated (i.e. the sum of the 24h, 48h and 72h scores for each animal divided by the observation number 3). The test subjects were evaluated for their eye irritation intensity according to the criteria of eye irritation response classification in tables 2-14 and tables 2-15 in the "disinfection Specification", 2.3.4, respectively, with average scores and recovery times for corneal, iris and conjunctival congestion and edema of the animals.
3. Experimental results
The "average score" for four aspects of corneal damage, iris damage, conjunctival congestion and conjunctival edema 24h, 48h and 72h after removal of the test subjects, and the type of injury of the multi-effect plant bacteriostatic antiviral agent to New Zealand rabbit eye irritation under the experimental conditions was non-irritating as shown in Table 14.
Table 14 eye irritation response score for new zealand rabbits
Note that: average score refers to the sum of 24h, 48h, 72h scores divided by the number of observation periods 3
Heavy metal detection:
The multi-effect plant antibacterial and antiviral preparation prepared in the example 1 is subjected to heavy metal (mercury, lead and arsenic) detection;
1. Detection equipment
1. Test sample: a multi-effect plant antibacterial and antiviral preparation stock solution.
2. Instrument apparatus: KC-SP-YQ-209 inductively coupled plasma Mass Spectrometry (iCAPRQ), KC-SP-YQ-051 electronic balance (AE 224C).
3. Reagent name and grade: nitric acid UP grade, 30% hydrogen peroxide superior grade purity, hydrochloric acid superior grade purity.
4. The standard solution concentration of lead and arsenic is 100 mug/mL, and the standard solution concentration of mercury is 1000 mug/mL.
2. Method of
1. The test basis is as follows: chapter 1.6 of cosmetic safety Specification (2015 edition).
2. Inspection conditions: the temperature was 19℃and the relative humidity was 40%.
3. Sample treatment: and (5) raw liquid.
3. Results
Lead and mercury in the stock solution of the multi-effect plant antibacterial and antiviral preparation are not detected, and the arsenic content is less than 0.0033mg/kg (minimum quantitative concentration). The results are shown in Table 15.
TABLE 15 lead, mercury, arsenic assay results
Microbiological index detection: the multi-effect plant antibacterial and antiviral preparation prepared in the example 1 is subjected to microbiological index detection;
1. Equipment and method for manufacturing the same
1. Test sample: a multi-effect plant antibacterial and antiviral preparation stock solution.
2. Instrument apparatus: KC-SP-YQ-594 super clean bench, KC-SP-YQ-180 electrothermal constant temperature incubator, KC-SPYQ-082 mould incubator.
2. Method of
1. The test basis is as follows: GB 15979-2002 appendix B of the Disposable sanitary Standard for sanitary articles.
2. Inspection conditions: the temperature was 21℃and the relative humidity was 52%.
3. Sample treatment: and (5) raw liquid.
3. Results
The total bacterial colony count and the total fungal colony count of the stock solution of the multi-effect plant antibacterial and antiviral preparation are all less than 1CFU/mL,
Coli, staphylococcus aureus, pseudomonas aeruginosa, and streptococcus hemolyticus were not detected. The results are shown in Table 16.
TABLE 16 microbiology index determination results
Claims (3)
1. A multi-effect plant antibacterial and antiviral preparation, which is characterized in that: comprises the following components in percentage by weight:
0.5% -1.8% of phyllanthus emblica extract;
0.5% -1.2% of lysozyme;
0.2% -0.8% of honeysuckle extract;
0.3% -0.8% of radix scutellariae extract;
Egg yolk immunoglobulin 0.2% -1.2%;
0.2% -0.8% of vitamin C;
3.0% -6.0% of xylitol;
Glycerol 1.0% -5.0%;
Poloxamer 0.3% -1.0%;
The balance of deionized water.
2. The multi-effect plant bacteriostatic antiviral preparation according to claim 1, characterized in that: comprises the following components in percentage by weight:
1.0% of phyllanthus emblica extract;
Lysozyme 1.0%;
0.5% of honeysuckle extract;
0.5% of scutellaria baicalensis extract;
Egg yolk immunoglobulin 0.5%;
Vitamin C0.5%;
Xylitol 5.0%;
Glycerol 3.0%;
Poloxamer 0.5%;
87.5 percent of deionized water.
3. The application provides a preparation method of a multi-effect plant antibacterial and antiviral preparation, which is characterized by comprising the following steps of:
S1: weighing the phyllanthus emblica extract, the honeysuckle extract, the baical skullcap root extract and deionized water according to the weight percentage, and adding the mixture into a liquid preparation tank;
S2: heating the liquid preparation tank and stirring to 80 ℃ to dissolve the materials;
S3: filtering the fully dissolved material for the first time, wherein the filtering precision is less than or equal to 5um;
S4: cooling the filtrate to 50deg.C, weighing and adding lysozyme, egg yolk immunoglobulin, vitamin C, xylitol, glycerol and poloxamer according to weight percentage, stirring for dissolving;
s5: and (3) carrying out secondary filtration on the dissolved material, wherein the filtration precision is less than or equal to 1.5um, and filling the material after inspection.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202410867601.6A CN118436778A (en) | 2024-07-01 | 2024-07-01 | Multi-effect plant antibacterial and antiviral preparation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202410867601.6A CN118436778A (en) | 2024-07-01 | 2024-07-01 | Multi-effect plant antibacterial and antiviral preparation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN118436778A true CN118436778A (en) | 2024-08-06 |
Family
ID=92328349
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202410867601.6A Pending CN118436778A (en) | 2024-07-01 | 2024-07-01 | Multi-effect plant antibacterial and antiviral preparation |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN118436778A (en) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101579523A (en) * | 2008-05-16 | 2009-11-18 | 上海白猫股份有限公司 | Egg yolk immunoglobulins oral and throat spraying agent and preparation method thereof |
| CN101816790A (en) * | 2010-05-06 | 2010-09-01 | 桂林莱茵生物科技股份有限公司 | Spray for treating radioactive xerostomia and preparation method thereof |
| CN104739719A (en) * | 2015-03-06 | 2015-07-01 | 吉林省现代中药工程研究中心有限公司 | Toothpaste capable of quickly relieving pain, diminishing inflammation, inhibiting bacteria, preventing dental caries and freshening breath |
| CN111643393A (en) * | 2020-07-13 | 2020-09-11 | 幽汰(福建)大健康产业有限公司 | Oral toothpaste for inhibiting helicobacter pylori and preparation device thereof |
| RO135969A2 (en) * | 2021-03-02 | 2022-09-30 | Marinela Ivănescu | Method for producing and characterizing the orodispersible powder with lysozyme and immunoglobulins y with nutritive, probiotic, antimicrobial and immunomodulating function: ylop |
-
2024
- 2024-07-01 CN CN202410867601.6A patent/CN118436778A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101579523A (en) * | 2008-05-16 | 2009-11-18 | 上海白猫股份有限公司 | Egg yolk immunoglobulins oral and throat spraying agent and preparation method thereof |
| CN101816790A (en) * | 2010-05-06 | 2010-09-01 | 桂林莱茵生物科技股份有限公司 | Spray for treating radioactive xerostomia and preparation method thereof |
| CN104739719A (en) * | 2015-03-06 | 2015-07-01 | 吉林省现代中药工程研究中心有限公司 | Toothpaste capable of quickly relieving pain, diminishing inflammation, inhibiting bacteria, preventing dental caries and freshening breath |
| CN111643393A (en) * | 2020-07-13 | 2020-09-11 | 幽汰(福建)大健康产业有限公司 | Oral toothpaste for inhibiting helicobacter pylori and preparation device thereof |
| RO135969A2 (en) * | 2021-03-02 | 2022-09-30 | Marinela Ivănescu | Method for producing and characterizing the orodispersible powder with lysozyme and immunoglobulins y with nutritive, probiotic, antimicrobial and immunomodulating function: ylop |
Non-Patent Citations (4)
| Title |
|---|
| 余主编: "医学微生物学", vol. 1, 31 July 1983, 人民卫生出版社出版, pages: 123 - 124 * |
| 刘志龙等主编: "万山草药", vol. 1, 31 January 2020, 河南科学技术出版社, pages: 245 * |
| 呙于明主编: "家禽营养", vol. 2, 30 September 2004, 中国农业大学出版社, pages: 437 * |
| 王炯等: "鸡卵抗体(IgY) 理化特性的研究", 中国生物制品学杂志, vol. 10, no. 3, 31 December 1997 (1997-12-31), pages 140 - 143 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105031609B (en) | The disinfectant and its preparation and use of the Cbf-14 containing antibacterial peptide | |
| WO2019144830A1 (en) | Broad lysis spectrum pseudomonas aeruginosa phage and disinfecting application thereof | |
| CN101543658B (en) | Cervical cap for preventing and treating cervical erosion and preparation method thereof | |
| FI66122C (en) | SAETT ATT FRAMSTAELLA ETT VACCIN VILKET AER ANVAENDBART FOERPROFYLAX OCH BEHANDLING AV TRIKOFYTOS HOS PAELSDJUR OCH KAN NER FOERORSAKAD AV EN PATOGEN ORGANISM TRICHOPHYTON MENTAGR PHYTES | |
| CN111700910A (en) | Cleaning disinfectant for preventing human from infecting animal germs | |
| EP0499015A1 (en) | Benzopyran phenol derivates for use as antibacterial, antiviral or immunostimulating agents | |
| CN114306511A (en) | Compound composition and application thereof in preparing medicine for preventing and treating skin diseases caused by malassezia bacteria | |
| CN109370908A (en) | A kind of culture of chicken coccidial oocyst and save liquid and its application | |
| CN110964700B (en) | Salmonella abortus phage and application thereof | |
| CN118436778A (en) | Multi-effect plant antibacterial and antiviral preparation | |
| KR101156082B1 (en) | Composition for treating bovine mastitis | |
| CN115770195B (en) | Stable acne-removing composition and preparation method thereof | |
| CN112662722A (en) | Dendrobium polypeptide extract with preservative effect and preparation method and application thereof | |
| CN115299443B (en) | Composition for inhibiting pathogenic microorganisms | |
| CN111328811B (en) | Low-concentration alcohol sterilization disinfectant and application thereof | |
| CN111821464B (en) | Live attenuated vaccine suspension for drinking water immunity and preparation method thereof | |
| US3197373A (en) | Immunological agent | |
| Hrytsenko et al. | The study of the antimicrobial activity of a soft dosage form with the antiviral effect | |
| CN114480302A (en) | Shewanella alga bacteriophage, bacteriophage composition and application thereof | |
| Vicas et al. | Chick Embryo Genotoxicity Analysis of the Green Medicine, Emblica officinalis Aqueous Extract, and Its Action on Endodontic Pathogens | |
| CN106619829A (en) | Medicine with resistance to staphylococcus aureus as well as preparation method and application of medicine | |
| CN113144177A (en) | Surface sterilization antiviral spray and preparation method and application thereof | |
| CN112516237A (en) | Sterilization and deodorization spray for pets and preparation method thereof | |
| CN111956672A (en) | Extraction and application of cordyceps militaris antibacterial active substance | |
| CN111202101A (en) | Anti-fogging disposable mask preparation liquid and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |